Therapeutic decisions under uncertainty for spinal muscular atrophy: The DECISIONS-SMA study protocol

PLoS One. 2022 Feb 15;17(2):e0264006. doi: 10.1371/journal.pone.0264006. eCollection 2022.

Abstract

Background: The therapeutic landscape for spinal muscular atrophy has changed in the last few years, encompassing respiratory/motor function and life expectancy benefits. However, physicians still have the challenge of tailoring individuals' treatment to therapeutic goals, disease progression, patient/caregiver's preferences, and personal experience to achieve an optimal risk/benefit balance. This study aims to provide insight into the preferred treatment choices of pediatric neurologists managing spinal muscular atrophy in their daily practice and to recognize behavioral factors that may influence decision-making.

Methods: This is a noninterventional, cross-sectional pilot study involving 50 pediatric neurologists managing spinal muscular atrophy in Spain. We designed an online platform that contains 13 simulated case scenarios of common presentations of patients with spinal muscular atrophy. The primary study outcome will be treatment preferences according to the percentages of participants who select treatment initiation when recommended, switch therapies when there is evidence of disease progression, and select treatment discontinuation when disease progression puts patients outside treatment recommendation (11 case scenarios). Secondary outcomes include therapeutic inertia prevalence (11 case scenarios), herding phenomenon prevalence (2 case scenarios), care-related regret prevalence (specific questions) and intensity (10-item Regret Intensity Scale), occupational burnout prevalence (nonproprietary single-item measure), and risk preferences (uncertainty test and risk aversion assessment).

Conclusions: The study findings will contribute to better understand relevant factors associated with therapeutic decisions of pediatric neurologists in spinal muscular atrophy, identifying treatment preferences and evaluating the role of behavioral aspects such as therapeutic inertia, herding, regret, and workplace burnout.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Burnout, Professional / epidemiology
  • Clinical Decision-Making / methods*
  • Cross-Sectional Studies
  • Disease Progression
  • Humans
  • Muscular Atrophy, Spinal / therapy*
  • Neurologists / psychology*
  • Patient Preference
  • Pediatrics
  • Pilot Projects

Grants and funding

The study was funded by Roche Medical Department, Spain (SL42765). The funding source had no role in the design, analysis and interpretation of the data, review or approval of the manuscript, and decision to submit for publication.